At least 14 million children are expected to face disruptions to essential nutrition support and services in 2025 because of ...

ONP-002 Advances Toward Phase IIa Concussion Trial with Strengthened Financial Foundation and Industry MomentumSARASOTA, Fla.

If we want to turn these short-term gains into sustainable change, we must fully unleash the potential of methadone-assisted ...

BioAtla Inc (BCAB) reports promising clinical progress and strategic initiatives, despite facing financial constraints and operational challenges.

Varied approaches to remote patient monitoring are in development to close care gaps between patients and rheumatologists, ...

Full-year results and business updateClinical proof of principle obtained in Phase I adjuvant head and neck cancer trial with individualized ...

Non-drug approaches can help people cope with stress and despair, says an expert. Read more at straitstimes.com.

With the newly completed OT-101 and IL-2 Phase 1 trial, Oncotelic is poised to begin further combination trials to determine the added efficacy of OT-101, IL-2, and CKIs in solid tumors such as lung ...

On track for multiple clinical updates through mid-2026, including further progress from two ongoing clinical programs and initiation of therapeutic dosing of potential new medicine, all based on our ...

Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, ...

- Jost Fischer, Chairman of AEON, will assume the role of interim CEO - ...

Pulse Biosciences, Inc. ( NASDAQ: PLSE) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Philip Trip Taylor - Investor Relations Paul LaViolette - Chief Executive Officer and Co-Chairman of ...